Early Infliximab Trough Levels Are Associated with Persistent Remission in Pediatric Patients with Inflammatory Bowel Disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Early Infliximab Trough Levels Are Associated with Persistent Remission in Pediatric Patients with Inflammatory Bowel Disease

Published:2014-10 Issue:10 Volume:20 Page:1708-1713
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:Inflammatory Bowel Diseases

Author:

Singh Namita,Rosenthal Casey J.,Melmed Gil Y.,Mirocha James,Farrior Sharmayne,Callejas Silvia,Tripuraneni Bhavna,Rabizadeh Shervin,Dubinsky Marla C.

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Reference18 articles.

1. Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn’s Disease in Children

2. Long-term outcome of maintenance infliximab therapy in children with Crohnʼs disease

3. Induction and Maintenance Therapy With Infliximab for Children With Moderate to Severe Ulcerative Colitis

4. Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn’s Disease

5. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

Cited by 136 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Different infliximab induction dosing regimens do not affect remission rates up to 1 year in children with Crohn's disease;Journal of Pediatric Gastroenterology and Nutrition;2024-07-09

2. Biomarkers predicting the effect of anti‐TNF treatment in paediatric and adult inflammatory bowel disease;Journal of Pediatric Gastroenterology and Nutrition;2024-05-02

3. Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease;Clinical Pharmacokinetics;2024-03-15

4. Infliximab Monotherapy vs Combination Therapy for Pediatric Crohn’s Disease Exhibit Similar Pharmacokinetics;Inflammatory Bowel Diseases;2024-01-03

5. Early infliximab trough levels in paediatric IBD patients predict sustained remission;Therapeutic Advances in Gastroenterology;2023-12-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3